REGENERATIVE THERAPIES MARKET ANALYSIS

The regenerative therapy market focuses on utilizing biological materials and innovative approaches to restore and regenerate damaged tissues and organs in the body.

According to the latest market report, the global regenerative therapies market was estimated to be valued at approximately US$ 93.56 billion in 2023. It is projected to reach a valuation of around US$ 259.36 billion by the year 2030, exhibiting a compound annual growth rate (CAGR) of approximately 15.7% during the forecast period of 2023-2030.

North America held dominant position in the global regenerative therapies market in 2022, accounting for 43.5% share in terms of value, followed by Europe and Asia Pacific, respectively

Analysts’ Views on Global Regenerative Therapies Market Market:

Regenerative therapies focus on stimulating the body's natural regenerative processes to restore or replace damaged tissues or organs. The market encompasses cell-based therapies, gene therapies, tissue engineering, and biomaterials. It has seen significant growth due to advances in biotechnology, increasing prevalence of chronic diseases, and supportive government initiatives. Challenges include complex manufacturing processes and high costs. Despite these challenges, regenerative therapies have the potential to revolutionize healthcare by offering transformative treatments. Ongoing research and technological advancements will further drive the market's growth.

Figure 1. Global Regenerative Therapies Market Share (%), Tissue Type, 2023

To learn more about this report, Request sample copy

Global Regenerative Therapies Market – Driver

 Growing Investments Drive Research and Collaboration in the Regenerative Medicine Market

Heightened investments in the regenerative medicine market have sparked extensive research and development initiatives, as numerous investors pour funds into start-up firms dedicated to advancing innovative therapies and products within the industry. Consequently, this has opened avenues for notable mergers, research collaborations, and partnerships, enabling the sharing of benefits derived from R&D endeavors.

Availability of Funding and Rising Investments Drive Regenerative Medicine Research

Increased funding and investments in the regenerative medicine field have spurred extensive research and development activities. The demand for improved therapies for various medical conditions has led to a surge in funding availability. Investments in the sector have reached significant levels, with key investors such as Amgen, Sanofi, and Gilead Sciences playing a prominent role. This financial support has facilitated the exploration of innovative solutions, including new cell therapies, gene therapies, and tissue-engineered products, driving advancements in regenerative medicine research.

For instance , The Alliance for Regenerative Medicine (ARM) reported that investments in the regenerative medicine sector reached USD 22,700 million in 2021. Key investors such as Amgen, Sanofi, and Gilead Sciences exceeded the previous year's total by surpassing USD 19,900 million in 2020.

In January 2022, the Royal College of Surgeons in Ireland (Ireland) received funding of US$ 226,000 from the European Commission to develop antioxidant-ion substituted nanoparticles for osteoporotic bone treatment.

The rising need for improved therapies for cancer, diabetes, skin diseases, musculoskeletal diseases, chronic wounds, burns, and CVD has resulted in increased research activities. Additionally, this has caused a surge in the availability of funding for regenerative medicine research. The new cell therapies, gene therapy, and tissue-engineered products are expensive in manufacturing & development; therefore, there is a rising need for funding. The investments in 2021 reached a substantial US$ 22.7 billion, surpassing the US$ 19.9 billion mark from 2020, with notable investors such as Amgen, AstraZeneca, Sanofi, and Gilead Sciences.

The increasing burden of chronic diseases is creating opportunities for market players in the regenerative therapies market. Major players are focusing on R&D to introduce new stem cell therapies, such as the identification of drug candidates for age-related macular degeneration using stem-cell-based research tools. These developments hold promise for addressing conditions with limited treatment options.

Figure 2. Global Regenerative Therapies Market Value (US$ Billion), By Region, 2023 

To learn more about this report, Request sample copy

Global Regenerative Therapies Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global Animal Healthcare  market over the forecast period. North America is e holding 49.3% of the market share in 2022. North America, with its major players and technological advancements in regenerative therapies, is estimated to dominate the market in terms of revenue. The U.S., within the region, experiences a high prevalence of diseases such as cancer and diabetes, which can be treated with stem cell therapies. The rising incidence of congenital heart defects and atrial fibrillation further contributes to the region's market growth potential. Regenerative medicine is seen as the future of healthcare, driving increasing popularity and demand in the region.

Global Regenerative Therapies Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of drugs from one place to another.

However, the global market was impacted differently by the outbreak of COVID-19, with varying effects on different segments. The tissue engineering segment experienced a significant decline, whereas the gene therapy segment witnessed strong growth, driven by consistent sales of rare disease therapeutics. Similarly, the platelet-rich plasma (PRP) segment declined in 2020, while the cell therapy segment exhibited a slightly higher growth rate during the same period.

For instance, as per a study published in September 2021 by the World Journal of Emergency Surgery During the COVID-19 pandemic, global road accidents decreased, resulting in fewer trauma center admissions and limited use of tissue engineered products. However, as pandemic restrictions eased in 2021, the regenerative therapy market rebounded. Significant regulatory approvals, including CAR-T cell therapies like ABECMA and BREYANZI by the U.S. FDA, and cell and gene therapies like Tecartus and Libmeldy by the EMA, further fueled market growth.

The regenerative therapy market is expected to see strong growth from 2022 onwards due to rising chronic diseases, driving research and development initiatives and new product launches.

Global Regenerative Therapies Market- Segmentation

The Global Animal helathcare Marketreport is segmented into By Tissue Type, By Application, By End User, By Region

By tissue Type, the market is segmented into allograft, xenograft, and alloplast globally, In the regenerative therapy market, allografts are currently the dominant segment. They involve using tissues or cells from a donor of the same species and are widely used in various medical procedures. Xenografts, which involve using tissues or cells from a different species, and alloplasts, which are synthetic materials, have a smaller market presence in comparison. However, ongoing advancements in xenografts and alloplasts may influence the market dynamics in the future.

By Application, the market is segmented into Soft Tissue Repair, Cardiovascular, Dental, Orthoped, CNS disease treatment, and Others.

By End user, market is segmented into hospitals, ambulatory surgical centers, and educational institutes. Hospitals are the dominant providers of regenerative therapy in the market, offering comprehensive patient care. Educational institutes contribute to research and development, while ambulatory surgical centers have a more limited role.

By Region, the market is segmented into north america, latin ameria, europe, asia pacific, middle east and africa. Out of which, the North America is expected to hold a dominant position in the  Regenerative Therapies Market during the forecast period, owing to increasing the usage of pharmaceuticals and vaccines.

Global Regenerative Therapies Market- Cross Sectional Analysis

The global regenerative therapies market presents significant growth potential and is driven by factors such as the increasing prevalence of chronic diseases and advancements in technology. It encompasses various therapeutic applications, including soft tissue repair, cardiovascular diseases, orthopedics, dental treatments, CNS disease treatment, and others. Hospitals play a crucial role as the primary providers of regenerative therapies, while ambulatory surgical centers offer specialized procedures. Educational institutes contribute to research and development, driving innovation in the field. Overall, the market is dynamic and offers opportunities for stakeholders to contribute to the advancement of regenerative medicine.

Global Regenerative Therapies Market: Key Developments

Regenerative medicine is diversifying its applications beyond tissue repair and wound care, extending into fields such as cardiology, neurology, oncology, and more. Companies are actively conducting clinical trials to establish their dominance by introducing innovative products and therapies, disrupting traditional treatment methods.

In June 11, 2022 - CRISPR (Clustered regularly interspaced short palindromic repeats) Therapeutics (Nasdaq: CRSP), a leading biopharmaceutical company specializing in the development of revolutionary gene-based treatments for severe illnesses, announced encouraging findings from their Phase 1 COBALT-LYM trial. The study assessed the safety and effectiveness of CTX130™, their proprietary allogeneic CAR-T cell therapy designed to target CD70, for the treatment of solid tumors and specific hematologic malignancies.

In April 2022, Metcela Inc. expanded its operations through the acquisition of Japan Regenerative Medicine Co., Ltd., a wholly-owned subsidiary of Kidswell Bio Co., Ltd. This strategic move enabled Metcela to broaden its product portfolio by incorporating JRM-001, an autologous cell product specifically designed for pediatric congenital heart disease. By integrating JRM-001 into its offerings, Metcela aimed to reinforce its clinical development infrastructure and accelerate the progress of these cutting-edge regenerative medicine solutions.

June 2022: Bristol Myers Squibb Company obtained U.S. FDA approval for Breyanzi, a CAR T cell therapy. It is specifically designed for patients with primary refractory or relapsed Large B-cell Lymphoma (LBCL) who are not eligible for transplant. This approval provides a promising treatment option for a subset of patients with limited alternatives.

June 2022: Avista Therapeutics entered into a partnership with F. Hoffmann La Roche Ltd to collaborate on the development of novel AAV gene therapy vectors for ocular diseases. This collaboration aims to leverage Avista's expertise in gene therapy and Roche's extensive capabilities in ocular disease research to advance innovative treatment options for patients with eye-related disorders.

Global Regenerative Therapies Market- Key Trends

Strategic acquisitions are driving the global regenerative medicine market as key players aim to enhance their R&D capabilities. Novel approaches using living cells, proteins, antibodies, and gene components have revolutionized chronic disease treatment. However, bridging the gap between expectations and practical implementation remains a challenge. To overcome this, companies are strategically acquiring resources to strengthen R&D and advance clinical applications. These initiatives accelerate the development and commercialization of regenerative therapies, meeting the demand for effective treatments.

April 2022: Metcela Inc. acquired Japan Regenerative Medicine Co., Ltd., a subsidiary of Kidswell Bio Co., Ltd. This acquisition enabled Metcela to incorporate JRM-001, an autologous cell product for pediatric congenital heart disease, into its product portfolio. The acquisition also enhanced Metcela's clinical development infrastructure for these regenerative medicine products.

January 2021: Integra LifeSciences acquired ACell, Inc. and its proprietary MatriStem UBM technologies. This strategic acquisition allowed Integra LifeSciences to expand its offerings in complex wound management solutions, providing more comprehensive treatment options for patients.

In April 2021, ExCellThera Inc., a clinical-stage company specializing in cell and molecular medicine, and Ossium Health, a therapeutics company focused on harnessing the potential of stem cell science for the treatment of blood and immune diseases, jointly announced a collaboration agreement. The purpose of this collaboration is to evaluate and explore opportunities to combine their respective capabilities, with the ultimate aim of advancing human health.

Global Regenerative Therapies Market: Restraint

Challenges in Market Growth: High Treatment Costs and Limited Reimbursement Policies The regenerative therapy market faces hurdles in its growth trajectory due to the high costs associated with treatment and inadequate reimbursement policies. This creates barriers for patients seeking these therapies. For example, many stem cell treatments are categorized as experimental, resulting in limited insurance coverage and significant out-of-pocket expenses for patients. Medicare, for instance, only covers U.S FDA-approved treatments such as allogeneic transplantation.

As per an article published by DVC Stem in July 2022, Stem cell therapy costs range from US$ 5,000 to US$ 50,000, depending on factors such as the type, number, and quality of cells used, as well as their source.

December 2021, Novartis's gene therapy product, Zolgensma, is a one-time treatment for spinal muscular atrophy with a price of US$ 2.12 million per infusion.

Global Regenerative Therapies Market - Key Players

Major players operating in the Regenerative Therapies Market include Shire Pharmaceuticals, Kinetic Concepts, Inc., Mesoblast Ltd., Metcela Inc., Nuo Therapeutics (Cytomedix Inc.), Integra LifeSciences, Advanced Cell Technology Inc., BioStem Life Sciences,Akron Biotechnology, LLC, Organovo Holdings Inc., Orgenesis Inc., Pluristem Therapeutics Inc., Genzyme, Athersys, Inc., RenovaCare, Inc., Cytori Therapeutics, Inc.

Definition: The global regenerative therapies market refers to the market for medical treatments and therapies that aim to restore, repair, or replace damaged or diseased cells, tissues, or organs using biological materials, such as stem cells, gene therapies, tissue engineering, and other advanced techniques. These therapies have the potential to revolutionize healthcare by offering new solutions for various chronic conditions and degenerative diseases.